Summary

KEY FINDINGS
The Europe Alzheimer’s disease therapeutics & diagnostics market is projected to develop with a CAGR of 6.07% over the forecast period 2024-2032. The market was valued at $2105.39 million in 2023 and is expected to reach a revenue of $3594.76 million by 2032.
MARKET INSIGHTS
The Europe Alzheimer's disease therapeutics & diagnostics market is experiencing substantial growth due to the rising prevalence of the condition and advancements in both therapeutic and diagnostic solutions. In essence, the demand for effective treatments, including disease-modifying therapies and early detection methods, such as biomarker-based diagnostics and advanced imaging techniques, is increasing. With a focus on improving patient outcomes through early intervention and personalized care, the market is benefiting from continuous research and development efforts. These innovations aim to address the growing need for more effective Alzheimer’s therapies and diagnostic tools, reducing the societal impact of the disease.
REGIONAL ANALYSIS
The Europe Alzheimer’s disease therapeutics & diagnostics market growth evaluation entails the assessment of the United Kingdom, Germany, France, Italy, Belgium, Poland, and Rest of Europe.
In the United Kingdom, the market is driven by a robust healthcare infrastructure, along with increasing government focus on dementia research and early diagnosis. The National Health Service (NHS) and various research initiatives contribute to advancing diagnostic technologies and the availability of therapeutics, positioning the UK as a key player in the Alzheimer’s market.
Germany, with its strong emphasis on medical innovation and research, is a major contributor to the Alzheimer’s disease therapeutics & diagnostics sector. The country benefits from its advanced healthcare system, which facilitates early detection and treatment options for Alzheimer’s disease. Additionally, the growing demand for disease-modifying therapies and diagnostic tools, coupled with Germany's leadership in the pharmaceutical and biotechnology industries, ensures continued market growth and development in the country.
In France, the market is expanding due to a rising aging population and a concerted push for better dementia care. France has been making vital investments in research, with numerous clinical trials and initiatives aimed at improving early diagnosis and treatment options. The country’s commitment to improving healthcare outcomes for Alzheimer's patients, combined with its growing focus on personalized medicine, further supports the market’s growth in the region.
SEGMENTATION ANALYSIS
The Europe Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further differentiated into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics).
Other therapeutics for Alzheimer's disease focus on disease-modifying treatments that target the underlying causes of the condition rather than just alleviating symptoms. One of the key approaches includes monoclonal antibodies, which are designed to target amyloid-beta plaques in the brain, a hallmark of Alzheimer's disease. Drugs like aducanumab and lecanemab are part of this class, and they work by reducing the buildup of amyloid plaques, which is believed to slow disease progression. These therapies aim to delay the cognitive decline associated with Alzheimer's and provide a potential for long-term management.
Additionally, tau-targeted therapies are another promising area in Alzheimer's treatment. These drugs aim to prevent the formation of tau tangles, another hallmark of the disease. By targeting tau, these treatments hope to protect the brain from neurodegeneration and preserve cognitive function. Other research is exploring anti-inflammatory and neuroprotective agents to address brain inflammation and protect neurons from further damage. As these therapies develop, they have the potential to provide a more comprehensive approach to treating Alzheimer's disease, improving outcomes for patients, particularly in the early to moderate stages of the condition.
COMPETITIVE INSIGHTS
Some of the leading players in the Europe Alzheimer’s disease therapeutics & diagnostics market include Allergan PLC (acquired by AbbVie), Biogen Inc, Cognoptix Inc, etc.
Allergan PLC, headquartered in Dublin, Ireland, operates in numerous countries, including the United States, Canada, China, India, and several high-growth markets across Europe, Southeast Asia, the Middle East, and Latin America. The company specializes in developing, manufacturing, marketing, and distributing branded biosimilar and over-the-counter (OTC) products. Moreover, in May 2020, AbbVie completed its acquisition of Allergan, and it is now part of AbbVie.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER’S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR EUROPE
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER’S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. GEOGRAPHICAL ANALYSIS
6.1. EUROPE
6.1.1. MARKET SIZE & ESTIMATES
6.1.2. EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET DRIVERS
6.1.3. EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET CHALLENGES
6.1.4. EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
6.1.5. KEY PLAYERS IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
6.1.6. COUNTRY ANALYSIS
6.1.6.1. UNITED KINGDOM
6.1.6.1.1. UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.2. GERMANY
6.1.6.2.1. GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.3. FRANCE
6.1.6.3.1. FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.4. ITALY
6.1.6.4.1. ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.5. BELGIUM
6.1.6.5.1. BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.6. POLAND
6.1.6.6.1. POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.7. REST OF EUROPE
6.1.6.7.1. REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. BAXTER INTERNATIONAL INC
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCT LIST
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCT LIST
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. BIOGEN INC
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCT LIST
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. COGNOPTIX INC
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCT LIST
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. ELI LILLY AND COMPANY
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCT LIST
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. F HOFFMANN-LA ROCHE
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCT LIST
7.2.6.3. STRENGTHS & CHALLENGES
7.2.7. LUPIN LIMITED
7.2.7.1. COMPANY OVERVIEW
7.2.7.2. PRODUCTS LIST
7.2.7.3. STRENGTHS & CHALLENGES
7.2.8. MERCK & CO INC
7.2.8.1. COMPANY OVERVIEW
7.2.8.2. PRODUCT LIST
7.2.8.3. STRENGTHS & CHALLENGES
7.2.9. NOVARTIS AG
7.2.9.1. COMPANY OVERVIEW
7.2.9.2. PRODUCTS LIST
7.2.9.3. STRENGTHS & CHALLENGES
7.2.10. SUN PHARMACEUTICALS INDUSTRIES LTD
7.2.10.1. COMPANY OVERVIEW
7.2.10.2. PRODUCT LIST
7.2.10.3. STRENGTHS & CHALLENGES
7.2.11. PFIZER INC
7.2.11.1. COMPANY OVERVIEW
7.2.11.2. PRODUCTS LIST
7.2.11.3. STRENGTHS & CHALLENGES
7.2.12. EISAI CO LTD
7.2.12.1. COMPANY OVERVIEW
7.2.12.2. PRODUCT LIST
7.2.12.3. STRENGTHS & CHALLENGES
7.2.13. JOHNSON & JOHNSON
7.2.13.1. COMPANY OVERVIEW
7.2.13.2. PRODUCT LIST
7.2.13.3. STRENGTHS & CHALLENGES
7.2.14. GE HEALTHCARE
7.2.14.1. COMPANY OVERVIEW
7.2.14.2. PRODUCT LIST
7.2.14.3. STRENGTHS & CHALLENGES